About Torrent Pharmaceuticals Ltd.



Torrent Pharmaceuticals Limited is an Indian pharmaceutical company based in Ahmedabad, Gujarat, India. It was initially promoted by Mr. UN Mehta as Trinity Laboratories in 1959 and later renamed Torrent Pharmaceuticals Limited in 1971. The company manufactures and sells branded generics, generic drugs and active pharmaceutical ingredient (APIs) both in India and internationally in 40+ countries like the US, Latin America, Russia & CIS, Europe, South East Asia, Asia Pacific, Africa & Middle East.


The company has wholly owned subsidiaries in USA, UK, Germany, Brazil, Russia, Mexico, Philippines and other major markets, and operates primarily in therapeutic areas such as Cardiovascular (CV), Central Nervous System (CNS), Gastrointestinal, Diabetology, Anti-infective and Pain Management, as well as other segments like Nephrology, Oncology, Gynecology and Pediatrics.


In 2014, Torrent acquired the branded domestic (i.e. India and Nepal) formulations business of Elder Pharmaceuticals – comprising 30 brands, including several leading brands in Women's Healthcare, Pain Management, Wound Care and Nutraceuticals.


As of 31st March 2015, the company (as per its website):

  • reported primary sales revenues from India (35%) and USA (18%)
  • had 3 manufacturing units (Gujarat, Himachal Pradesh & Sikkim), and a fourth one coming up (Dahej, Gujarat)
  • had 1 R&D facility (India) with 660 scientists
  • was the sole manufacturer of Insulin Formulations for Novo Nordisk in India
  • had several first time product introductions to its credit (72 in India and 2 worldwide)


Torrent Pharmaceuticals Limited is listed on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE).


Torrent Pharmaceuticals Limited at-a-glance

  • Employees 10,044
  • Turnover (31 March, 2015) ~USD 684 m
  • Product Registrations 1200
  • Markets Served (countries) 40+
  • Manufacturing Facilities 3
  • First Time Introductions (India) 72
  • First Time Introductions (world) 2

Approvals Regulatory Approvals


BFARM (Germany)


Ministry of Health, (UAE)

TGA (Australia)

Ukraine Drugs Authority, (Ukraine)

National Drug Authority, (Uganda)

Pharmacy and Poison Board (Kenya)

Medicinal Control Authority of Zimbabwe, (Zimbabwe)

Gulf Cooperation council, (Gulf Countries)

ANMAT, (Argentina)

GMP, (Canada)


MCC, (South Africa)

INVIMA (Columbia)






em>Quality Certifications

Health, Safety (ISO-18001-2007)

Environment System (ISO-14001-2004)

Quality System Management (ISO 9001-2008)

Energy Management System (ISO 50001-2011)

5 Star Rating & Sword of Honor Award by British Safety Council

*Source: http://www.torrentpharma.com/, http://www.torrentpharma.com/compliances.php,




  • 1959 – Founded by Mr. UN Mehta as Trinity Laboratories
  • 1971 – Renamed Torrent Pharmaceuticals Limited
  • 1980 – Establishes first manufacturing facility at Vatva in Ahmedabad, Gujarat
    • 1983 – Receives first export order to USSR
    • 1984
      • Receives Chemexcil Export Award
      • Receives Udyog Ratna Award
    • 1985

      • Receives Chemexcil Export Award.
      • Receives IDMA Quality Excellence Award
      • Receives Export Award grom Govt. of Gujarat
      • Receives IMC Golden Jubilee Endowment Award for Export Performance
    • 1986

      • Receives Chemexcil Export Award
      • Receives IDMA Quality Excellence Award
      • Receives Export Award from Govt. of Gujarat
    • 1987

      • Receives Chemexcil Export Award
      • Receives Export Award from Govt. of Gujarat
    • 1988 – Receives Chemexcil Export Award
    • 1989
      • Commissions second manufacturing plant at Indrad
      • Receives Chemexcil Trishul Award for highest Pharma Exports
      • Receives IDMA Quality Excellence Award
    • 1990

      • Receives National Export Award
      • Receives Pride of Asia International Award for excellence in Pharmaceuticals Products by International Friendship
    • 1992 – Receives IDMA Quality Excellence Award
    • 1995 – Commissions Torrent Gujarat Biotech Limited plant
    • 1996 – Founder UN Mehta bestowed with Corporate Business Man of the Year title
    • 1998

      • Torrent Exports renamed Torrent Ltd.
      • Commissions state-of-the-art R&D Centre
      • Acquires pharma related investments and business of Torrent Exports Limited
    • 1999

      • Torrent Pharmaceuticals Ltd. is restructured through formation of 3 new divisions – Prima, Vista, Psycan
      • Patents first new chemical via Torrent Research Center
      • Wins GCCI Export Appreciation Award
      • Bags Gold Trophy for IDMA Quality Excellence Award for formulations facility
    • 2000

      • Bags Gold Trophy for IDMA Quality Excellence Award for formulations facility
      • Receives OECD Standards of Good Lab. Practices Certificate from Dutch Health Ministry
    • 2001

      • Receives ISO 9001:2000 Certificate for Indrad Plant
      • Ranked in the top 10 Indian Companies based on Return on Capital Employed (ET - BCG Study Feb - 2001)
      • Wins 'Best Suppliers' award from Sri Lanka State Pharmaceutical Corporation
      • Wins Gold Trophy for IDMA Quality Excellence Award for formulations facility, and Silver Trophy for API manufacturing facility
    • 2002

      • Sets up Torrent do Brasil Ltda. in Brazil
      • Discovers and patents AGE (Advanced Glycosylation End-products) molecule
      • Receives ISO 14001:1996 and OHSAS 18001:1999 for Indrad Plant
      • Receives ISO/IEC 17025:1999 for its R&D Centre from National Accreditation Board for Testing and Calibration Laboratories (NABL).
      • Torrent Research Center develops Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System and Multiparticulate/ Matrix Based SR/ Modified Release Formulations
      • Wins Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
    • 2003

      • Brazilian Sanitary Surveillance Agency accredits R&D Centre with ANVISA, authorizing Bioequivalance Studies
      • Sets up Torrent Pharma Inc. in USA
      • Receives GMP Certification from European Union
      • Receives MCC South Africa approval for Indrad Plant
    • 2004

      • Sets up Torrent Pharma Philippines Inc.
      • Receives MHRA (UK) and TGA (Australia) approvals for Indrad manufacturing facility
    • 2005

      • Sets up Torrent Australasia Pty Ltd. in Australia
      • Sets up new manufacturing unit at Baddi, Himachal Pradesh, to cater to domestic formulations market
      • Signs agreement with Novo Nordisk India to establish a new, dedicated formulation and packaging unit for Insulin for Novo Nordisk
      • Acquires Heumann Pharma GmbH & Co Generica KG, a Pfizer group company, in Germany
      • Sets up 2 new marketing divisions for neuropsychiatry segment
      • Enters into research collaboration with AstraZeneca for developing novel anti-hypertensive drug
      • Receives ISO/IEC- 17025 from NABL for Chhatral plant’s QC department
    • 2006 – Receives USFDA approval for API and formulations manufacturing facilities at Indrad, Gujarat

    • 2007

      • Signs technical agreement for product supplies with Pharma Dynamics (Pty) Ltd, South Africa
      • Receives ISO 9001: 2000 (Quality Management System), ISO 14001:2004 (Environmental Management System) and OHSAS 180001:1999 (Occupational Health and Safety Management System) by ISOQAR, UKAS accredited body for Indrad plant
    • 2008 – Receives GMP certification from Government of Upper Bavaria, Germany for Baddi plant

    • 2009

      • Commissions dedicated formulation and packaging unit for manufacturing Insulin exclusively for Novo Nordisk
      • Enters into license and supply agreement with AstraZeneca for marketing its products internationally
    • 2010

      • Receives Five Star rating from British Safety Council for Baddi plant
      • Receives OHAS Audit 18001:2007certification from Uganda’s regulatory authority for Baddi plan
      • Commences commercial operations of Laboratories Torrent S.A. de C.V., Mexico
      • Starts construction of Dahej manufacturing facility
      • Commissions a subsidiary in United Kingdom and Romania
      • Develops Long Acting Injectables technology
    • 2011

      • Commences production in Sikkim


      • Develops Nasal Drug Delivery system

    • 2012

      • Receives Sword of Honor for Occupational Health & Safety from British Safety Council for Indrad plant
    • 2013 – Develops Topical Foams system
    • 2014

      • Enters into licensing agreement with Reliance Life Sciences for 3 biosimilars – Rituximab, Adalimumab and Cetuximab
      • Acquires Elder Pharma’s Indentified Indian Branded Formulation Business in India and Nepal
    • 2015

      • Commences operations at Dahej plant
      • Recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards (2014)
      • Acquires 100% stake of Zyg Pharma



  • Founder: Mr. UN Mehta
  • Chairman Emeritus: Mr. Sudhir Mehta
  • Executive Chairman: Mr. Samir Mehta
  • Directors Mr. Markand Bhatt, Mr. Shailesh Haribhakti, Mr. Haigreve Khaitan, Mr. Pradeep Bhargava, Prof. Ashish Nanda, Dr. Chaitanya Dutt (R&D)


Torrent Pharmaceuticals Limited Contact Details


Off. Ashram Road

Ahmedabad – 380 009.

Gujarat, India

Tel: 91(0)79-26585090/3060

Fax: 91(0)79-26582100


Website: http://www.torrentpharma.com/


For business development

Mr. Gaurav Jain

Torrent Pharma Inc.

150 Allen Road, Suite 102

Basking Ridge,

NJ 07920, USA

Email: gauravjain@torrentpharma.us

For general inquires

Torrent Pharma Inc.

150 Allen Road, Suite 102

Basking Ridge,

NJ 07920, USA

Tel: +1-908-280-3333

Fax: +1-908-280-3363

For sales inquiries

Email: sales@torrentpharma.us


For customer service


Email: customerservice@torrentpharma.us


Mr. Naimi Kapashi

Torrent Do Brasil Ltda

Rua Henri Dunant, 1383

Morumbi Corporate Towers

Golden Tower - 24th floor;

Santo Amaro

São Paulo - SP- 04709-111


Tel: +55-11-5501-2585

Fax: +55-11-55012586

Email: naimi@torrent.com.br


For general inquires


Paseo de las Palmas No.765, Oficina

304, Col. Lomas de Chapultepec, 11000

Mexico DF


Tel: +52(55)5202 0856

For business development etc.

Email: suprit@torrentpharma.com.mx



Mr. Jinesh Shah

Torrent Pharmaceuticals Ltd.

117418, Moscow

Russia 61, Novocheremyshkinskaya

Tel: +7 495 258 59 90

Fax: +7 495 258 59 89


Email: jineshshah@torrentpharma.com


Mr Amul Agrawal

Torrent Pharma GmbH

Südwestpark 50

90449 Nürnberg



Tel: +49 911 4302 970


Fax: +49 911 4302 971


Email: mail@torrentpharma.de



* Indicates mandatory field.
Please wait while comments are being sent...